Edwards Lifesciences Corp (Edwards Lifesciences) is a company focused on structural heart innovation, primarily engaged in developing and providing surgical and transcatheter therapies for cardiovascular diseases. The company offers a range of repair and replacement technologies for heart valves, including aortic, mitral, tricuspid, and pulmonic valves. Edwards Lifesciences serves the healthcare industry, particularly clinicians and healthcare stakeholders, by providing medical technologies designed to improve patient outcomes in the treatment of cardiovascular diseases.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Edwards Lifesciences's R&D arm focuses on therapies with the potential to change the practice of medicine for structural heart patients. The company's key areas of investment included transcatheter structural heart programs, clinical research for mitral, aortic, and tricuspid therapies, and the development of new products to improve transcatheter aortic heart valve replacement procedures. The company is also engaged in ongoing research to enhance current products and expand their applications, with a focus on structural heart disease. Clinical trials and evidence collection for regulatory submissions and post-market studies are significant components of the R&D efforts. The R&D activities of Edwards Lifesciences are conducted primarily in facilities located in the US and Israel. The experienced R&D staff focuses on product design and development, quality, clinical research, and regulatory compliance. The company has developed alliances with leading research institutions and universities and collaborates with clinicians worldwide to conduct scientific studies on existing and developing products. In FY2025, the company spent US$1,079.2 million on its R&D activities, which as a percentage of revenue, stood at 17.8%.